Daiichi Sankyo Begins the P-III (QuANTUM-Wild) Study of Vanflyta (Quizartinib) to Treat FLT3-ITD Negative Acute Myeloid Leukemia (AML)
Shots:
- The first patient has been dosed with Vanflyta + standard CT in P-III (QuANTUM-Wild) study, built on P-II (QUIWI) trial assessing Vanflyta with standard intensive CT and as subsequent maintenance monotx.
- The trial will involve newly diagnosed FLT3-ITD-ve AML patients (n= ~700; 18-70yrs.) divided across 3 arms, Vanflyta (arm A) or PBO (arm B) + cytarabine & anthracycline induction, then cytarabine consolidation CT, followed by maintenance therapy for up to 3yrs. in the US, EU, Asia & Australia
- Arm C will explore Vanflyta with induction & consolidation CT followed by PBO maintenance for exploratory analysis. The 1EP is OS & 2EPs are EFS, CR duration & rate, CR with MRD negativity, relapse-free survival, PK & safety
Ref: Daiichi Sankyo | Image: Daiichi Sankyo
Related News:- Daiichi Sankyo Reports Pooled Analysis from TROPION-Lung05 & TROPION-Lung01 Trials of Datopotamab Deruxtecan (Dato-DXd) for NSCLC
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
Click here to read the full press release
Disha is a content writer at PharmaShots. She is passionate and curious about recent updates and developments in MedTech and Pharma industry. She covers news related to clinical trial results and updates. She can be contacted at connect@pharmashots.com.
